Frost & Sullivan

JULY 31, 2024

This shift is benefiting pharmaceutical companies and contract research organizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.

Retail 52

Retail Contract research organization Utilities 52

Frost & Sullivan

JULY 31, 2024

This shift is benefiting pharmaceutical companies and contract research organizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.

Retail 52

Retail Contract research organization Utilities 52

Frost & Sullivan

AUGUST 29, 2024

This is fueling the growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) driving industry growth. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%.

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

AUGUST 6, 2023

San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contract research organization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%

Biotechnology 52

Biotechnology Biotech Contract research organization Biopharmaceuticals 52

Frost & Sullivan

MARCH 22, 2024

Growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth. Top 10 pharma companies contribute only 4-5% to R&D pipeline; top 25 contribute less than 10%.

Biopharma 52

Biopharma Ecosystems Biotech Contract research organization 52

Frost & Sullivan

FEBRUARY 15, 2024

Utilize this distinctive competitive benchmarking tool to elevate your future growth potential significantly. The Frost Radar™ serves as a powerful analytical tool for conducting a comprehensive ‘Growth Audit’ across various industries, evaluating key companies on essential criteria related to innovation and growth.

Ecosystems 40

Ecosystems Contract research organization Biotech Utilities 40

Frost & Sullivan

MAY 9, 2025

The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). The global CRO industry, valued at $66.39

Mergers and acquisition activities 52

Mergers and acquisition activities Biopharma Biotechnology Biotech 52